2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts

The healthcare industry has been a remarkable place for investors to build significant portfolio returns through the years. Companies that are providing life-saving medicines, devices, and other products are often at the forefront of innovation in the healthcare space, a durable industry that tends to be broadly resilient even in times of economic unrest.If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one with an average 12-month price forecast of 29% (which is still nearly three times as much as the average annual stock-market return) and one with an average 12-month price forecast in multibagger territory. Both growth profiles could add value to a long-term portfolio. So here are two companies you won't want to overlook the next time you go shopping for investments.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool